CDMO

Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Venture Capital, Manufacturing, Finance, Pharmaceutical, Professional Services, Oncology, Practice Management, Mental Health, Research, Science, Other Manufacturing, COVID-19, CDMO, Patient, Psychological abuse, NIH, Clinical trial, Ground substance, National Institutes of Health, API, NCE, Pain management, Bangladesh Technical Education Board, Multimedia, Government, New chemical entity, Fine chemical

This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.

Key Points: 
  • This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • View the full release here: https://www.businesswire.com/news/home/20240314509251/en/
    The strategic combination of Noramco, Purisys, and Halo Pharma unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • Lee Karras, CEO of the Noramco Group, emphasized the importance of this alignment in the current market, stating, "The COVID-19 pandemic exposed critical vulnerabilities in our drug supply chain.
  • To explore how the Noramco Group can support API to drug product supply needs, visit www.noramco.com .

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, Failure, CDMO, Acceleration, News, Relevant, Bank statement, Interest, Debt-to-GDP ratio, Security (finance)

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO).
  • Investors who purchased Avid Bioservices securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CDMO .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities

Retrieved on: 
Wednesday, March 13, 2024
Other Manufacturing, Research, Packaging, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, CDMO, Growth, ATS, ICP-OES, Patient, LGM, History, ICP-MS, Kinetics, Senior, Doctor of Philosophy, Nausea, Quality, Traction, API, Operation, Fine chemical

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

Key Points: 
  • LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
  • With a broad array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups.
  • In addition to analytical testing, the company provides comprehensive method development and validation services, as well as stability testing, including real-time and accelerated stability studies.
  • “As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, Telephone, Debt-to-GDP ratio, Suite, CDMO, News, Acceleration

Law Offices of Howard G. Smith announces an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) investors concerning the Company’s possible violations of federal securities laws.
  • On March 6, 2024, Avid disclosed that it had received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026.
  • On this news, Avid’s stock price fell $2.69, or 30.6%, to close at $6.10 per share on March 7, 2024, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

Retrieved on: 
Wednesday, March 13, 2024
Class Action Lawsuit, Professional Services, Legal, Debt-to-GDP ratio, Suite, CDMO, Law, News, Acceleration, Security (finance)

The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • On March 6, 2024, Avid disclosed that it had received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026.
  • On this news, Avid’s stock price fell $2.69, or 30.6%, to close at $6.10 per share on March 7, 2024, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence

Retrieved on: 
Tuesday, March 12, 2024
Other Manufacturing, Medical Devices, Clinical Trials, Health Technology, Stem Cells, Manufacturing, Biotechnology, General Health, Pharmaceutical, Health, Failure, CDMO, Patient, CGMP, Good manufacturing practice, Safety, Workforce, Patient safety, Multimedia

The Cell Shuttle is an automated, ultra-high throughput, cell therapy manufacturing platform designed to meet global patient demand while reducing costs and process failure rates.

Key Points: 
  • The Cell Shuttle is an automated, ultra-high throughput, cell therapy manufacturing platform designed to meet global patient demand while reducing costs and process failure rates.
  • The release of this new version of the Cell Shuttle platform is an important milestone on the way to ensuring clinical readiness by the end of 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240312686211/en/
    First cGMP Cell Shuttle & Cellares co-founders Omar Kurdi (left) and Fabian Gerlinghaus (right).
  • For more information about Cellares’ cGMP Cell Shuttle, please visit cellares.com/technology

Simtra BioPharma Solutions Recognized by Customers as a Service Champion and for excellence in all six categories at the 2024 CDMO Leadership Awards

Retrieved on: 
Thursday, March 28, 2024
CDMO, Organization, Patient, Research, Compatibility, ISR, Overalls, Service, Fine chemical

PARSIPPANY, N.J., March 28, 2024 /PRNewswire-PRWeb/ -- Simtra BioPharma Solutions, a premier injectable contract development and manufacturing organization (CDMO), proudly announces its outstanding achievement for the 11th year at the CDMO Leadership Awards, clinching an impressive total of 6 awards. This remarkable feat highlights Simtra's commitment to excellence in contract manufacturing and underscores its position as a leader in the industry.

Key Points: 
  • ...These awards underscore our pursuit of setting a new standard for excellence in our industry, delivering innovative solutions, and surpassing the expectations of our clients.
  • Among the awards received, Simtra excelled across most of the categories, further affirming Simtra's ability to cater to diverse client needs.
  • Simtra BioPharma Solutions' unwavering dedication to integrity, quality, technical expertise and customer satisfaction has distinguished it as a leader in the industry.
  • "We are honored to receive such prestigious recognition from our valued customers," said Franco Negron, CEO of Simtra BioPharma Solutions.

Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report

Retrieved on: 
Wednesday, March 27, 2024
Carbon, Element, Carbon footprint, Health, Culture, CDMO, Waste management, Organization, Consciousness, Learning, Biophysical environment, Recycling, ESG, Science, Human, Woman, Social, PCI, Safety, Water, Supplier, DEI

PHILADELPHIA, March 27, 2024 /PRNewswire/ -- PCI Pharma Services, ("PCI") a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report. A detailed overview of PCI's multifaceted sustainability journey, the report showcases the strides taken from the program's formal inception in 2021 through its 2023 fiscal year, and lays out ambitious goals for continued progress along multiple fronts.

Key Points: 
  • PHILADELPHIA, March 27, 2024 /PRNewswire/ -- PCI Pharma Services, ("PCI") a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report .
  • True to this mindset, PCI Pharma's ESG program is inherently inclusive and bottom-up.
  • Other highlights from PCI's ESG report include:
    Carbon footprint targets and strategy were developed in alignment to Science Based Targets.
  • "Although we at PCI formally established our ESG Program in 2021, our ESG consciousness is by no means new," said Salim Haffar, CEO of PCI Pharma Services.

Abzena Announces Major Investment in Bioconjugation and ADC Capabilities in Response to Increasing Industry Demand

Retrieved on: 
Wednesday, March 27, 2024
CGMP, Patient, Quality control, ADC, CDMO, Pressure, Investment, Fine chemical

The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site's existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.

Key Points: 
  • The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site's existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.
  • This latest investment provides a major boost to the Bristol facility by expanding and optimizing the site's Quality Control (QC) and analytical laboratory layouts and technologies, allowing for increased efficiencies in response to customer demand.
  • To complement the site's newly expanded analytical capabilities , Abzena has also invested in a Sartorius Hipersep® Flowdrive Pilot System to enhance purification processes for clinical manufacturing batches.
  • Abzena has additional investments planned in both development and manufacturing areas at the Bristol, PA facility that will be completed over the course of 2024.